Picton Mahoney Asset Management Has $16.91 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Picton Mahoney Asset Management boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 20.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,236 shares of the medical device company’s stock after acquiring an additional 23,595 shares during the quarter. Picton Mahoney Asset Management’s holdings in DexCom were worth $16,905,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Winslow Capital Management LLC bought a new stake in DexCom during the third quarter worth about $173,120,000. Vaughan Nelson Investment Management L.P. grew its position in DexCom by 16,943.0% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock worth $136,193,000 after acquiring an additional 1,451,165 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in DexCom by 79.3% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,847,865 shares of the medical device company’s stock valued at $172,406,000 after purchasing an additional 817,351 shares in the last quarter. TimesSquare Capital Management LLC raised its position in DexCom by 11,359.1% in the 3rd quarter. TimesSquare Capital Management LLC now owns 733,380 shares of the medical device company’s stock valued at $68,424,000 after purchasing an additional 726,980 shares during the last quarter. Finally, Natixis Advisors L.P. boosted its stake in DexCom by 141.4% in the fourth quarter. Natixis Advisors L.P. now owns 1,129,570 shares of the medical device company’s stock worth $140,168,000 after purchasing an additional 661,584 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Trading Up 0.3 %

Shares of DXCM stock traded up $0.45 on Tuesday, reaching $130.10. The company had a trading volume of 1,425,158 shares, compared to its average volume of 2,999,962. The stock has a market cap of $51.74 billion, a PE ratio of 83.94, a PEG ratio of 2.19 and a beta of 1.23. The company has a 50-day moving average of $132.67 and a 200-day moving average of $121.11. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. On average, equities analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on DXCM. Raymond James raised their target price on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada initiated coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. UBS Group boosted their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $141.67.

Insider Activity at DexCom

In other news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total value of $79,411.25. Following the sale, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Insiders sold a total of 190,004 shares of company stock worth $25,610,270 in the last quarter. Corporate insiders own 0.41% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.